Enanta Pharma (ENTA) Tops Q1 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019
February 6, 2020 4:00 PM ESTWebcast and Conference Call Today at 4:30 p.m. ET
Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects- Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients Research and development programs progressing well -- several milestones expected in 2020 from our RSV, NASH, and HBV programs Royalty revenue for the quarter was $52.6 million Cash and marketable securities totaled $414.7 million at December 31, 2019
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:... More
